Short-term immunotherapy using an allergy vaccine adjuvanted with monophosphoryl lipid A: A post-marketing surveillance study

International Review of Allergology and Clinical Immunology

Volumn 8, Issue 4, 2002, Pages 219-223

  Drachenberg, K J ^a   Proll S ^a   Urban, E ^a   Woroniecki, S R ^b  

^a Bencard Allergie GmbH   (Germany)

^b Allergy Therapeutics Ltd   (United Kingdom)

Author keywords

Asthma; Efficacy; MPL; Rhinoconjunctivitis; Short term immunotherapy; SIT; Tolerability; Vaccine

Indexed keywords

ALLERGEN; ALLERGY VACCINE; MPL; PHOSPHORYL LIPID A; POLLINEX; UNCLASSIFIED DRUG; VACCINE;

ADULT; ALLERGY; ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MARKETING; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; GRASS; HUMAN; IMMUNOTHERAPY; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; POLLEN; POLLINATION; PRESCRIPTION; PRURITUS; RESPIRATORY TRACT ALLERGY; RHINITIS; RHINOCONJUNCTIVITIS; RYE; SEASONAL VARIATION; SYSTEMIC DISEASE; TREATMENT OUTCOME; TREE; URTICARIA; VACCINATION;

EID: 0036969065     PISSN: 12329142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Bousquet J. Et al.: Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO position paper. Allergy, 1998, 53 (Suppl.), 1-42.
2. Brewer J.M. et al.: Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4 or IL-13-mediated signalling. J. Immunol., 1999, 163, 6448-6454.
3. Drachenberg K.J. et al.: A well-tolerated grass-pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy, 2001, 56, 498-505.
4. Durham S.R., Till S.J.: Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol., 1998, 102, 157-164.
5. Hopkins M. et al.: Standardisation of glutaraldehyde-modifled tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL®). Allergol. et Immunopathol., 2001, 29(6), 245-254.
6. Möller C. et al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-Study). J. Allergy Clin. Immunol., 2002, 109 (2), 251-256.
7. Mothes N. Et al.: Immunotherapy with a tyrosine-adsorbed, monophosphoryl lipid A-adjuvanted grass-pollen allergoid: reduced seasonally boosted IgE production and inhibition of basophil histamine release by therapy-induced IgG antibodies (Abstract). Allergy, 2002, 57, suppl. 73, 52.
8. Röver A.C. et al.: Immunophenotypic characterization of peripheral B cells during short-term immunotherapy with tree pollen allergoid and the immunoadjuvant monophosphoryl lipid A. (Abstract). Allergy, 2002, 57, suppl. 73, 67-68.
9. Wheeler A.W. et al.: A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol., 2001, 126, 135-139.